A Phase 3 interventional study of Levonorgestrel IUD (LCS, BAY86-5028) and Yasmin (EE30/DRSP, BAY86-5131) in Contraception, sponsored by Bayer. Completed at 94 sites in 5 countries. Open to female participants aged 18 Years to 29 Years. Per ClinicalTrials.gov, last updated 2017-09-25.
Sponsored by Bayer · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The primary objective of this study is to evaluate user satisfaction and tolerability in young women (18-29 years of age) using the LCS12 compared with young women using a COC (Yasmin) over a period of 18 months. Subjects in the LCS12 arm will be offered continued use of LCS12 for the full, intended duration of use (up to 3 years) by continuing in a optional, extension phase. Safety data only will be collected during the extension phase of the study.
Secondary objectives are to observe the tolerability, discontinuation rates, adverse event profiles, occurrences of unintended pregnancies (including calculation of Pearl Index [PI]), and bleeding profiles with the two birth-control methods. Additionally, data on missed tablets in the combined oral contraceptive (COC) group, and intrauterine delivery system (IUS) expulsions in the LCS12 group will be recorded. In the LCS12 group, physician satisfaction with the IUS inserter, evaluation of the visibility and texture of the removal threads, and evaluation of the visibility of the LCS12 on ultrasound (in a subset of subjects) will be collected. Finally, in the COC group, information will be collected on the psychosocial impact of missed or delayed pill intake.
Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.
Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
In the opinion of the investigator, the subject is
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received LCS12 (low dose levonorgestrel \[LNG\] intrauterine delivery system \[IUS\]) with an initial in vitro release rate of 12 μg LNG per day for 18 months with optional extension to 36 months
Drug: Levonorgestrel IUD (LCS, BAY86-5028)
Participants received combined oral contraceptive (COC) tablet Yasmin containing 30 μg ethinyl estradiol (EE) and 3 mg drospirenone (DRSP) for 18 months/19 cycles
Drug: Yasmin (EE30/DRSP, BAY86-5131)
LCS12 insertion will occur at randomization visit (Visit 2). Duration of study treatment is 18 months with optional extension to 36 months for subjects in this group only.
Drug page: Drospirenone and ethinyl estradiol combination
Combined oral contraceptive (COC; Yasmin; 0.03 mg ethinyl estradiol and 3 mg drospirenone); Subjects will start taking COC at / on the day of visit 2 and continue taking one pill / day without any breaks for the entire study duration of 18 months.
Overall Satisfaction Rate at 18 Months (Last Observation Carried Forward, LOCF)
Satisfaction was to be assessed by the subject based on a 5-point Likert item, using the following question: How satisfied are you with the birth control method used during the study? 1. Very satisfied 2. Satisfied 3. Neither satisfied nor dissatisfied 4. Dissatisfied 5. Very dissatisfied The overall satisfaction rate was to be the percentage of subjects selecting "1. Very satisfied" or "2. Satisfied" for the above question.
Time frame: At 18 months
Overall Satisfaction Rating by the 5-point Likert Item at 6 Months
Satisfaction was to be assessed by the subject based on a 5-point Likert item, using the following question: How satisfied are you with the birth control method used during the study? 1. Very satisfied 2. Satisfied 3. Neither satisfied nor dissatisfied 4. Dissatisfied 5. Very dissatisfied The overall satisfaction rate was to be the percentage of subjects selecting "1. Very satisfied" or "2. Satisfied" for the above question.
Time frame: At 6 months
Overall Satisfaction Rating by the 5-point Likert Item at 12 Months
Satisfaction was to be assessed by the subject based on a 5-point Likert item, using the following question: How satisfied are you with the birth control method used during the study? 1. Very satisfied 2. Satisfied 3. Neither satisfied nor dissatisfied 4. Dissatisfied 5. Very dissatisfied The overall satisfaction rate was to be the percentage of subjects selecting "1. Very satisfied" or "2. Satisfied" for the above question.
Time frame: At 12 months
Overall Satisfaction Rating by the 5-point Likert Item at 18 Months
Satisfaction was to be assessed by the subject based on a 5-point Likert item, using the following question: How satisfied are you with the birth control method used during the study? 1. Very satisfied 2. Satisfied 3. Neither satisfied nor dissatisfied 4. Dissatisfied 5. Very dissatisfied The overall satisfaction rate was to be the percentage of subjects selecting "1. Very satisfied" or "2. Satisfied" for the above question.
Time frame: At 18 months
Overall Satisfaction Rating by the 5-point Likert Item at End of Study (EOS)
Satisfaction was to be assessed by the subject based on a 5-point Likert item, using the following question: How satisfied are you with the birth control method used during the study? 1. Very satisfied 2. Satisfied 3. Neither satisfied nor dissatisfied 4. Dissatisfied 5. Very dissatisfied The overall satisfaction rate was to be the percentage of subjects selecting "1. Very satisfied" or "2. Satisfied" for the above question. The 18-month Treatment Visit served as the End-of-Study (EOS) Visit for participant in the COC group and LCS12 participant who did not enter the Extension Phase.
Time frame: At 18 months/EOS
Overall Satisfaction Rate at 6 Months (LOCF)
Satisfaction was to be assessed by the subject based on a 5-point Likert item, using the following question: How satisfied are you with the birth control method used during the study? 1. Very satisfied 2. Satisfied 3. Neither satisfied nor dissatisfied 4. Dissatisfied 5. Very dissatisfied The overall satisfaction rate was to be the percentage of subjects selecting "1. Very satisfied" or "2. Satisfied" for the above question.
Time frame: At 6 months
Overall Satisfaction Rate at 12 Months (LOCF)
Satisfaction was to be assessed by the subject based on a 5-point Likert item, using the following question: How satisfied are you with the birth control method used during the study? 1. Very satisfied 2. Satisfied 3. Neither satisfied nor dissatisfied 4. Dissatisfied 5. Very dissatisfied The overall satisfaction rate was to be the percentage of subjects selecting "1. Very satisfied" or "2. Satisfied" for the above question.
Time frame: At 12 months
User Satisfaction - Acceptability of the Administration of Study Treatment
The 18-month Treatment Visit served as the End-of-Study (EOS) Visit for participant in the COC group and LCS12 participant who did not enter the Extension Phase.
Time frame: At 18 months/EOS
User Satisfaction - Choices Upon Completion of the Study
The 18-month Treatment Visit served as the End-of-Study (EOS) Visit for participant in the COC group and LCS12 participant who did not enter the Extension Phase.
Time frame: At 18 months/EOS
User Satisfaction - Amount of Menstrual Bleeding
The 18-month Treatment Visit served as the End-of-Study (EOS) Visit for participant in the COC group and LCS12 participant who did not enter the Extension Phase.
Time frame: At 18 months/EOS
User Satisfaction - Satisfaction With Menstrual Bleeding Pattern
The 18-month Treatment Visit served as the End-of-Study (EOS) Visit for participant in the COC group and LCS12 participant who did not enter the Extension Phase.
Time frame: At 18 months/EOS
User Satisfaction - Frequency of Experiencing Unexpected Bleeding
The 18-month Treatment Visit served as the End-of-Study (EOS) Visit for participant in the COC group and LCS12 participant who did not enter the Extension Phase.
Time frame: At 18 months/EOS
User Satisfaction - Satisfaction With Menstrual Bleeding Absence
The 18-month Treatment Visit served as the End-of-Study (EOS) Visit for participant in the COC group and LCS12 participant who did not enter the Extension Phase.
Time frame: At 18 months/EOS
User Satisfaction - Comparison of Menstrual Pain Intensity Between Now and Before Treatment
The 18-month Treatment Visit served as the End-of-Study (EOS) Visit for participant in the COC group and LCS12 participant who did not enter the Extension Phase.
Time frame: At 18 months/EOS
User Satisfaction - Rating of Usual Menstrual Pain Intensity
The 18-month Treatment Visit served as the End-of-Study (EOS) Visit for participant in the COC group and LCS12 participant who did not enter the Extension Phase.
Time frame: At 18 months/EOS
EVAPIL-R Scores at Screening - Composite Score
The EVAPIL-R scale is a self-questionnaire aimed to assess tolerability of oral contraceptives. A composite score was derived from 16 items and the ratings for presence/absence (rated as 1/0), frequency (rated with values from 0 to 2), intensity (rated from 1 to 3) and bother (rated from 1 to 4) for each item. To calculate the composite score, the bother rating of each item was multiplied by an item- specific multiplier and a weight. Range is 0-12, with higher values indicating more severe symptoms/less tolerability.
Time frame: At screening
EVAPIL-R Scores at Screening - Bother Score
The EVAPIL-R scale is a self-questionnaire aimed to assess tolerability of oral contraceptives. A composite score was derived from 16 items and the ratings for presence/absence (rated as 1/0), frequency (rated with values from 0 to 2), intensity (rated from 1 to 3) and bother (rated from 1 to 4) for each item. To calculate the composite score, the bother rating of each item was multiplied by an item- specific multiplier and a weight. Range is 0-12, , with higher values indicating more severe symptoms/less tolerability.
Time frame: At screening
EVAPIL-R Scores at 6 Months
The EVAPIL-R scale is a self-questionnaire aimed to assess tolerability of oral contraceptives. A composite score was derived from 16 items and the ratings for presence/absence (rated as 1/0), frequency (rated with values from 0 to 2), intensity (rated from 1 to 3) and bother (rated from 1 to 4) for each item. To calculate the composite score, the bother rating of each item was multiplied by an item- specific multiplier and a weight. Range is 0-12, with higher values indicating more severe symptoms/less tolerability.
Time frame: At 6 months
EVAPIL-R Scores at 12 Months - Bother Score
The EVAPIL-R scale is a self-questionnaire aimed to assess tolerability of oral contraceptives. A composite score was derived from 16 items and the ratings for presence/absence (rated as 1/0), frequency (rated with values from 0 to 2), intensity (rated from 1 to 3) and bother (rated from 1 to 4) for each item. To calculate the composite score, the bother rating of each item was multiplied by an item- specific multiplier and a weight. Range is 0-12, with higher values indicating more severe symptoms/less tolerability.
Time frame: At 12 months
EVAPIL-R Scores at 12 Months - Composite Score
The EVAPIL-R scale is a self-questionnaire aimed to assess tolerability of oral contraceptives. A composite score was derived from 16 items and the ratings for presence/absence (rated as 1/0), frequency (rated with values from 0 to 2), intensity (rated from 1 to 3) and bother (rated from 1 to 4) for each item. To calculate the composite score, the bother rating of each item was multiplied by an item- specific multiplier and a weight. Range is 0-12, with higher values indicating more severe symptoms/less tolerability.
Time frame: At 12 months
EVAPIL-R Scores at 18 Months/EOS
The EVAPIL-R scale is a self-questionnaire aimed to assess tolerability of oral contraceptives. A composite score was derived from 16 items and the ratings for presence/absence (rated as 1/0), frequency (rated with values from 0 to 2), intensity (rated from 1 to 3) and bother (rated from 1 to 4) for each item. To calculate the composite score, the bother rating of each item was multiplied by an item- specific multiplier and a weight. Range is 0-12, with higher values indicating more severe symptoms/less tolerability. The 18-month Treatment Visit served as the End-of-Study (EOS) Visit for participant in the COC group and LCS12 participant who did not enter the Extension Phase.
Time frame: At 18 months/EOS
Cumulative Drop-out Rate
The drop-out rate is the amount of participants that could not complete the study for various reasons. Discontinuation rates due to the following reasons and overall discontinuations were calculated: • LCS12 expulsions • Bleeding pattern alterations • Bleeding pattern alterations with increased bleeding (amount) • Bleeding pattern alterations with decreased bleeding (amount) • Adverse Events The analyses described above were also done by parity. Furthermore, overall discontinuation rates were analyzed by Kaplan-Meier analyses and presented as cumulative half-yearly drop-out rates.
Time frame: Up to 6, 12, 18, 24 and 36 months
Pearl Index (PI)
The Pearl Index was defined as the number of pregnancies per 100 woman years (WYs). Given the assumption that the number of pregnancies follows a Poisson distribution, the Pearl Index thus is the mean of this distribution.
Time frame: Up to 18, 24, 36 months
Compliance Rate for Yasmin Pill Intake
Time frame: Up to 18 months
User Satisfaction - Acceptability of the Administration of Study Treatment
The degree of user satisfaction was assessed at the end-of-study visit using an eight item questionnaire. One of the items assessed was acceptability of study treatment which was categorized into the following: acceptable without I/D, acceptable with some I/D, not acceptable with moderate I/D, and not acceptable with extreme I/D.
Time frame: At 6 months
User Satisfaction - Acceptability of the Administration of Study Treatment
The degree of user satisfaction was assessed at the end-of-study visit using an eight item questionnaire. One of the items assessed was acceptability of study treatment which was categorized into the following: acceptable without I/D, acceptable with some I/D, not acceptable with moderate I/D, and not acceptable with extreme I/D.
Time frame: At 12 months
Cumulative Number of Participants With Partial or Total Expulsion
Total expulsion is confirmed if the IUS is observed in the vagina, the IUS is not shown in the uterine cavity by ultrasound, and / or the subject confirms that the system was expelled. Partial expulsion is diagnosed if the IUS can be partially seen in the vagina or is displaced in the cervical canal.
Time frame: Up to 18, 24, 36 months
Investigator's Evaluation of Successful IUS Insertion Procedure
Time frame: Up to 18 months
Participants' Evaluation of Pain During Successful IUS Insertion Procedure
Time frame: Up to 18 months
Investigator's Evaluation of IUS Removal Procedure
Time frame: Up to 36 months
Participants' Evaluation of Pain During IUS Removal Procedure
Time frame: Up to 36 months
The study was conducted in 42 centers across 4 countries in Austria, Belgium, Germany and United States.
| Milestone | LCS12 (Skyla, BAY86-5028) | EE30/DRSP (Yasmin, BAY86-5131) |
|---|---|---|
| Started | 282 | 285 |
| Participants received treatment | 279 | 281 |
| Completed | 227 | 204 |
| Not completed | 55 | 81 |
| Withdrew: Adverse event | 25 | 25 |
| Withdrew: Lost to follow-up | 3 | 21 |
| Withdrew: Pregnancy | 2 | 6 |
| Withdrew: Withdrawal by subject | 20 | 21 |
| Withdrew: Protocol violation | 1 | 2 |
| Withdrew: Wish for pregnancy | 4 | 6 |
| Milestone | LCS12 (Skyla, BAY86-5028) | EE30/DRSP (Yasmin, BAY86-5131) |
|---|---|---|
| Started | 200 | 0 |
| Completed | 163 | 0 |
| Not completed | 37 | 0 |
| Withdrew: Wish for pregnancy | 14 | 0 |
| Withdrew: Adverse event | 9 | 0 |
| Withdrew: Withdrawal by subject | 7 | 0 |
| Withdrew: Other unknown | 4 | 0 |
| Withdrew: Pregnancy | 2 | 0 |
| Withdrew: Lost to follow-up | 1 | 0 |
Satisfaction was to be assessed by the subject based on a 5-point Likert item, using the following question: How satisfied are you with the birth control method used during the study? 1. Very satisfied 2. Satisfied 3. Neither satisfied nor dissatisfied 4. Dissatisfied 5. Very dissatisfied The overall satisfaction rate was to be the percentage of subjects selecting "1. Very satisfied" or "2. Satisfied" for the above question.
| Percentage of participants | LCS12 (Skyla, BAY86-5028) | EE30/DRSP (Yasmin, BAY86-5131) |
|---|---|---|
| Overall Satisfaction Rate at 18 Months (Last Observation Carried Forward, LOCF) | 82.1 | 81.9 |
Satisfaction was to be assessed by the subject based on a 5-point Likert item, using the following question: How satisfied are you with the birth control method used during the study? 1. Very satisfied 2. Satisfied 3. Neither satisfied nor dissatisfied 4. Dissatisfied 5. Very dissatisfied The overall satisfaction rate was to be the percentage of subjects selecting "1. Very satisfied" or "2. Satisfied" for the above question.
| Percentage of participants | LCS12 (Skyla, BAY86-5028) | EE30/DRSP (Yasmin, BAY86-5131) |
|---|---|---|
| Very Satisfied | 60.4 | 48.1 |
| Satisfied | 27.5 | 35.8 |
| Neither satisfied nor dissatisfied | 7.3 | 9.6 |
| Dissatisfied | 1.8 | 6.2 |
| Very Dissatisfied | 2.9 | 0.4 |
Satisfaction was to be assessed by the subject based on a 5-point Likert item, using the following question: How satisfied are you with the birth control method used during the study? 1. Very satisfied 2. Satisfied 3. Neither satisfied nor dissatisfied 4. Dissatisfied 5. Very dissatisfied The overall satisfaction rate was to be the percentage of subjects selecting "1. Very satisfied" or "2. Satisfied" for the above question.
| Percentage of participants | LCS12 (Skyla, BAY86-5028) | EE30/DRSP (Yasmin, BAY86-5131) |
|---|---|---|
| Very Satisfied | 66.8 | 45.0 |
| Satisfied | 22.9 | 44.1 |
| Neither satisfied nor dissatisfied | 5.9 | 5.9 |
| Dissatisfied | 4.3 | 3.8 |
| Very Dissatisfied | 0.0 | 1.3 |
Satisfaction was to be assessed by the subject based on a 5-point Likert item, using the following question: How satisfied are you with the birth control method used during the study? 1. Very satisfied 2. Satisfied 3. Neither satisfied nor dissatisfied 4. Dissatisfied 5. Very dissatisfied The overall satisfaction rate was to be the percentage of subjects selecting "1. Very satisfied" or "2. Satisfied" for the above question.
| Percentage of participants | LCS12 (Skyla, BAY86-5028) | EE30/DRSP (Yasmin, BAY86-5131) |
|---|---|---|
| Very Satisfied | 64.3 | 52.5 |
| Satisfied | 25.1 | 37.8 |
| Neither satisfied nor dissatisfied | 6.4 | 6.9 |
| Dissatisfied | 3.0 | 2.8 |
| Very Dissatisfied | 1.3 | 0.0 |
Satisfaction was to be assessed by the subject based on a 5-point Likert item, using the following question: How satisfied are you with the birth control method used during the study? 1. Very satisfied 2. Satisfied 3. Neither satisfied nor dissatisfied 4. Dissatisfied 5. Very dissatisfied The overall satisfaction rate was to be the percentage of subjects selecting "1. Very satisfied" or "2. Satisfied" for the above question. The 18-month Treatment Visit served as the End-of-Study (EOS) Visit for participant in the COC group and LCS12 participant who did not enter the Extension Phase.
| Percentage of participants | LCS12 (Skyla, BAY86-5028) | EE30/DRSP (Yasmin, BAY86-5131) |
|---|---|---|
| Very Satisfied | 58.6 | 46.6 |
| Satisfied | 23.5 | 35.1 |
| Neither satisfied nor dissatisfied | 8.6 | 9.6 |
| Dissatisfied | 5.6 | 7.6 |
| Very Dissatisfied | 3.7 | 1.2 |
Satisfaction was to be assessed by the subject based on a 5-point Likert item, using the following question: How satisfied are you with the birth control method used during the study? 1. Very satisfied 2. Satisfied 3. Neither satisfied nor dissatisfied 4. Dissatisfied 5. Very dissatisfied The overall satisfaction rate was to be the percentage of subjects selecting "1. Very satisfied" or "2. Satisfied" for the above question.
| Percentage of participants | LCS12 (Skyla, BAY86-5028) | EE30/DRSP (Yasmin, BAY86-5131) |
|---|---|---|
| Overall Satisfaction Rate at 6 Months (LOCF) | 87.9 | 83.8 |
Satisfaction was to be assessed by the subject based on a 5-point Likert item, using the following question: How satisfied are you with the birth control method used during the study? 1. Very satisfied 2. Satisfied 3. Neither satisfied nor dissatisfied 4. Dissatisfied 5. Very dissatisfied The overall satisfaction rate was to be the percentage of subjects selecting "1. Very satisfied" or "2. Satisfied" for the above question.
| Percentage of participants | LCS12 (Skyla, BAY86-5028) | EE30/DRSP (Yasmin, BAY86-5131) |
|---|---|---|
| Overall Satisfaction Rate at 12 Months (LOCF) | 84.3 | 83.8 |
The 18-month Treatment Visit served as the End-of-Study (EOS) Visit for participant in the COC group and LCS12 participant who did not enter the Extension Phase.
| Participants | LCS12 (Skyla, BAY86-5028) | EE30/DRSP (Yasmin, BAY86-5131) |
|---|---|---|
| Acc. without inconvenience/discomfort | 153 | 186 |
| Acc. with some inconv/discomfort | 87 | 46 |
| Not acc. with moderate inconv./discomf. | 11 | 15 |
| Not acc. with extreme inconv./discomf | 12 | 3 |
The 18-month Treatment Visit served as the End-of-Study (EOS) Visit for participant in the COC group and LCS12 participant who did not enter the Extension Phase.
| Participants | LCS12 (Skyla, BAY86-5028) | EE30/DRSP (Yasmin, BAY86-5131) |
|---|---|---|
| Continue with study treatment | 174 | 122 |
| Use a different hormonal contraceptive | 34 | 51 |
| Use a different contraceptive method | 17 | 27 |
| Discont. use of all types of contracept. | 6 | 14 |
| No need for contraceptive at this time | 5 | 12 |
| Undecided | 27 | 22 |
The 18-month Treatment Visit served as the End-of-Study (EOS) Visit for participant in the COC group and LCS12 participant who did not enter the Extension Phase.
| Participants | LCS12 (Skyla, BAY86-5028) | EE30/DRSP (Yasmin, BAY86-5131) |
|---|---|---|
| Decreased | 80 | 35 |
| Not Changed | 163 | 207 |
| Increased | 17 | 8 |
The 18-month Treatment Visit served as the End-of-Study (EOS) Visit for participant in the COC group and LCS12 participant who did not enter the Extension Phase.
| Participants | LCS12 (Skyla, BAY86-5028) | EE30/DRSP (Yasmin, BAY86-5131) |
|---|---|---|
| Very satisfied | 101 | 91 |
| Somewhat satisfied | 65 | 84 |
| Neither satisfied nor dissatisfied | 48 | 68 |
| Dissatisfied | 19 | 4 |
| Very dissatisfied | 10 | 1 |
| Not applicable | 20 | 2 |
The 18-month Treatment Visit served as the End-of-Study (EOS) Visit for participant in the COC group and LCS12 participant who did not enter the Extension Phase.
| Participants | LCS12 (Skyla, BAY86-5028) | EE30/DRSP (Yasmin, BAY86-5131) |
|---|---|---|
| Never | 145 | 219 |
| Seldom | 92 | 25 |
| Often | 17 | 5 |
| Very Often | 9 | 1 |
The 18-month Treatment Visit served as the End-of-Study (EOS) Visit for participant in the COC group and LCS12 participant who did not enter the Extension Phase.
| Participants | LCS12 (Skyla, BAY86-5028) | EE30/DRSP (Yasmin, BAY86-5131) |
|---|---|---|
| Very satisfied | 96 | 6 |
| Somewhat satisfied | 18 | 0 |
| Neither satisfied nor dissatisfied | 14 | 8 |
| Dissatisfied | 1 | 0 |
| Very dissatisfied | 1 | 0 |
The 18-month Treatment Visit served as the End-of-Study (EOS) Visit for participant in the COC group and LCS12 participant who did not enter the Extension Phase.
| Participants | LCS12 (Skyla, BAY86-5028) | EE30/DRSP (Yasmin, BAY86-5131) |
|---|---|---|
| Decreased | 118 | 61 |
| Not changed | 102 | 169 |
| Increased | 39 | 17 |
The 18-month Treatment Visit served as the End-of-Study (EOS) Visit for participant in the COC group and LCS12 participant who did not enter the Extension Phase.
| Participants | LCS12 (Skyla, BAY86-5028) | EE30/DRSP (Yasmin, BAY86-5131) |
|---|---|---|
| None | 124 | 82 |
| Mild | 78 | 92 |
| Moderate | 43 | 67 |
| Severe | 16 | 8 |
The EVAPIL-R scale is a self-questionnaire aimed to assess tolerability of oral contraceptives. A composite score was derived from 16 items and the ratings for presence/absence (rated as 1/0), frequency (rated with values from 0 to 2), intensity (rated from 1 to 3) and bother (rated from 1 to 4) for each item. To calculate the composite score, the bother rating of each item was multiplied by an item- specific multiplier and a weight. Range is 0-12, with higher values indicating more severe symptoms/less tolerability.
| Scores on a scale | LCS12 (Skyla, BAY86-5028) | EE30/DRSP (Yasmin, BAY86-5131) |
|---|---|---|
| EVAPIL-R Scores at Screening - Composite Score | 0.9386 ± 0.8036 | 0.8846 ± 0.8231 |
The EVAPIL-R scale is a self-questionnaire aimed to assess tolerability of oral contraceptives. A composite score was derived from 16 items and the ratings for presence/absence (rated as 1/0), frequency (rated with values from 0 to 2), intensity (rated from 1 to 3) and bother (rated from 1 to 4) for each item. To calculate the composite score, the bother rating of each item was multiplied by an item- specific multiplier and a weight. Range is 0-12, , with higher values indicating more severe symptoms/less tolerability.
| Scores on a scale | LCS12 (Skyla, BAY86-5028) | EE30/DRSP (Yasmin, BAY86-5131) |
|---|---|---|
| EVAPIL-R Scores at Screening - Bother Score | 0.5569 ± 0.4451 | 0.5188 ± 0.4406 |
The EVAPIL-R scale is a self-questionnaire aimed to assess tolerability of oral contraceptives. A composite score was derived from 16 items and the ratings for presence/absence (rated as 1/0), frequency (rated with values from 0 to 2), intensity (rated from 1 to 3) and bother (rated from 1 to 4) for each item. To calculate the composite score, the bother rating of each item was multiplied by an item- specific multiplier and a weight. Range is 0-12, with higher values indicating more severe symptoms/less tolerability.
| Scores on a scale | LCS12 (Skyla, BAY86-5028) | EE30/DRSP (Yasmin, BAY86-5131) |
|---|---|---|
| Composite score | 1.3187 ± 0.9888 | 1.1537 ± 0.9947 |
| Bother score | 0.7364 ± 0.4940 | 0.6550 ± 0.5148 |
The EVAPIL-R scale is a self-questionnaire aimed to assess tolerability of oral contraceptives. A composite score was derived from 16 items and the ratings for presence/absence (rated as 1/0), frequency (rated with values from 0 to 2), intensity (rated from 1 to 3) and bother (rated from 1 to 4) for each item. To calculate the composite score, the bother rating of each item was multiplied by an item- specific multiplier and a weight. Range is 0-12, with higher values indicating more severe symptoms/less tolerability.
| Scores on a scale | LCS12 (Skyla, BAY86-5028) | EE30/DRSP (Yasmin, BAY86-5131) |
|---|---|---|
| EVAPIL-R Scores at 12 Months - Bother Score | 0.7789 ± 0.5120 | 0.6015 ± 0.4663 |
The EVAPIL-R scale is a self-questionnaire aimed to assess tolerability of oral contraceptives. A composite score was derived from 16 items and the ratings for presence/absence (rated as 1/0), frequency (rated with values from 0 to 2), intensity (rated from 1 to 3) and bother (rated from 1 to 4) for each item. To calculate the composite score, the bother rating of each item was multiplied by an item- specific multiplier and a weight. Range is 0-12, with higher values indicating more severe symptoms/less tolerability.
| Scores on a scale | LCS12 (Skyla, BAY86-5028) | EE30/DRSP (Yasmin, BAY86-5131) |
|---|---|---|
| EVAPIL-R Scores at 12 Months - Composite Score | 1.4022 ± 1.0126 | 1.0535 ± 0.8698 |
The EVAPIL-R scale is a self-questionnaire aimed to assess tolerability of oral contraceptives. A composite score was derived from 16 items and the ratings for presence/absence (rated as 1/0), frequency (rated with values from 0 to 2), intensity (rated from 1 to 3) and bother (rated from 1 to 4) for each item. To calculate the composite score, the bother rating of each item was multiplied by an item- specific multiplier and a weight. Range is 0-12, with higher values indicating more severe symptoms/less tolerability. The 18-month Treatment Visit served as the End-of-Study (EOS) Visit for participant in the COC group and LCS12 participant who did not enter the Extension Phase.
| Scores on a scale | LCS12 (Skyla, BAY86-5028) | EE30/DRSP (Yasmin, BAY86-5131) |
|---|---|---|
| Composite score | 1.4804 ± 1.1926 | 1.0246 ± 0.9546 |
| Bother score | 0.8113 ± 0.5765 | 0.5908 ± 0.4836 |
The drop-out rate is the amount of participants that could not complete the study for various reasons. Discontinuation rates due to the following reasons and overall discontinuations were calculated: • LCS12 expulsions • Bleeding pattern alterations • Bleeding pattern alterations with increased bleeding (amount) • Bleeding pattern alterations with decreased bleeding (amount) • Adverse Events The analyses described above were also done by parity. Furthermore, overall discontinuation rates were analyzed by Kaplan-Meier analyses and presented as cumulative half-yearly drop-out rates.
| Percentage of participants | LCS12 (Skyla, BAY86-5028) | EE30/DRSP (Yasmin, BAY86-5131) |
|---|---|---|
| Up to 6 months | 7.53 | 11.39 |
| Up to 12 months | 13.26 | 21.71 |
| Up to 18 months | 18.64 | 27.40 |
| Up to 24 months | 30.85 | NA |
| Up to 36 months | 33.34 | NA |
The Pearl Index was defined as the number of pregnancies per 100 woman years (WYs). Given the assumption that the number of pregnancies follows a Poisson distribution, the Pearl Index thus is the mean of this distribution.
| Pregnancies per 100 women years | LCS12 (Skyla, BAY86-5028) | EE30/DRSP (Yasmin, BAY86-5131) |
|---|---|---|
| Pearl index up to 18 months | 0.57 (0.07 to 2.05) | 1.82 (0.67 to 3.97) |
| Pearl index up to 24 months | 0.67 (0.14 to 1.95) | NA (NA to NA) |
| Pearl index up to 36 months | 0.65 (0.18 to 1.67) | NA (NA to NA) |
| Percentage of participants | EE30/DRSP (Yasmin, BAY86-5131) |
|---|---|
| Missing | 2.8 |
| Compliance <=75% | 2.1 |
| Compliance >75% | 95.0 |
Total expulsion is confirmed if the IUS is observed in the vagina, the IUS is not shown in the uterine cavity by ultrasound, and / or the subject confirms that the system was expelled. Partial expulsion is diagnosed if the IUS can be partially seen in the vagina or is displaced in the cervical canal.
| Participants | LCS12 (Skyla, BAY86-5028) |
|---|---|
| Partial expulsion up to 18 months | 0 |
| Total expulsion up to 18 months | 0 |
| Partial expulsion up to 24 months | 1 |
| Total expulsion up to 24 months | 0 |
| Partial expulsion up to 36 months | 1 |
| Total expulsion up to 36 months | 0 |
| Participants | LCS12 (Skyla, BAY86-5028) |
|---|---|
| Easy | 247 |
| Slightly difficult | 31 |
| Very difficult | 1 |
| Participants | LCS12 (Skyla, BAY86-5028) |
|---|---|
| None | 49 |
| Mild | 125 |
| Moderate | 80 |
| Severe | 25 |
| Participants | LCS12 (Skyla, BAY86-5028) |
|---|---|
| Easy | 252 |
| Slightly difficult | 11 |
| Very difficult | 4 |
| Participants | LCS12 (Skyla, BAY86-5028) |
|---|---|
| None | 136 |
| Mild | 96 |
| Moderate | 30 |
| Severe | 5 |
The degree of user satisfaction was assessed at the end-of-study visit using an eight item questionnaire. One of the items assessed was acceptability of study treatment which was categorized into the following: acceptable without I/D, acceptable with some I/D, not acceptable with moderate I/D, and not acceptable with extreme I/D.
| Participants | LCS12 (Skyla, BAY86-5028) | EE30/DRSP (Yasmin, BAY86-5131) |
|---|---|---|
| Acc. without inconvenience/discomfort | 163 | 192 |
| Acc. with some inconv/discomfort | 87 | 48 |
| Not acc. with moderate inconv./discomf. | 4 | 4 |
| Not acc. with extreme inconv./discomf. | 2 | 0 |
The degree of user satisfaction was assessed at the end-of-study visit using an eight item questionnaire. One of the items assessed was acceptability of study treatment which was categorized into the following: acceptable without I/D, acceptable with some I/D, not acceptable with moderate I/D, and not acceptable with extreme I/D.
| Participants | LCS12 (Skyla, BAY86-5028) | EE30/DRSP (Yasmin, BAY86-5131) |
|---|---|---|
| Acc. without inconvenience/discomfort | 152 | 185 |
| Acc. with some inconv/discomfort | 74 | 33 |
| Not acc. with moderate inconv./discomf. | 9 | 2 |
| Not acc. with extreme inconv./discomf. | 1 | 0 |
Collected over From start of treatment until 36 months/EOS visit.. Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| LCS12 (Skyla, BAY86-5028) | — | 22/279 (7.9%) | 215/279 (77.1%) |
| EE30/DRSP (Yasmin, BAY86-5131) | — | 5/281 (1.8%) | 148/281 (52.7%) |
| Event | LCS12 (Skyla, BAY86-5028) | EE30/DRSP (Yasmin, BAY86-5131) |
|---|---|---|
| Ectopic pregnancyPregnancy, puerperium and perinatal conditions | 3/279 | 0/281 |
| Ligament ruptureInjury, poisoning and procedural complications | 2/279 | 0/281 |
| AppendicitisInfections and infestations | 1/279 | 2/281 |
| AppendicitisInfections and infestations | 1/279 | 2/281 |
| Basedow's diseaseEndocrine disorders | 1/279 | 0/281 |
| Colitis ulcerativeGastrointestinal disorders | 1/279 | 0/281 |
| Femoral herniaGastrointestinal disorders | 1/279 | 0/281 |
| LacerationInjury, poisoning and procedural complications | 1/279 | 0/281 |
| Ligament ruptureInjury, poisoning and procedural complications | 1/279 | 0/281 |
| ExostosisMusculoskeletal and connective tissue disorders | 1/279 | 0/281 |
| Event | LCS12 (Skyla, BAY86-5028) | EE30/DRSP (Yasmin, BAY86-5131) |
|---|---|---|
| DysmenorrhoeaReproductive system and breast disorders | 48/279 | 26/281 |
| DysmenorrhoeaReproductive system and breast disorders | 47/279 | 26/281 |
| Cervical dysplasiaReproductive system and breast disorders | 35/279 | 16/281 |
| AcneSkin and subcutaneous tissue disorders | 34/279 | 6/281 |
| HeadacheNervous system disorders | 21/279 | 33/281 |
| HeadacheNervous system disorders | 26/279 | 32/281 |
| AcneSkin and subcutaneous tissue disorders | 30/279 | 6/281 |
| Cervical dysplasiaReproductive system and breast disorders | 25/279 | 16/281 |
| Abdominal painGastrointestinal disorders | 23/279 | 4/281 |
| CystitisInfections and infestations | 23/279 | 15/281 |
| Age, Continuous(Years) | LCS12 (Skyla, BAY86-5028) | EE30/DRSP (Yasmin, BAY86-5131) | Total |
|---|---|---|---|
| Mean | 23.7 ± 3.0 | 23.9 ± 3.0 | 23.8 ± 3.0 |
| Sex: Female, Male(Participants) | LCS12 (Skyla, BAY86-5028) | EE30/DRSP (Yasmin, BAY86-5131) | Total |
|---|---|---|---|
| Female | 279 | 281 | 560 |
| Male | 0 | 0 | 0 |
| Number of births(Participants) | LCS12 (Skyla, BAY86-5028) | EE30/DRSP (Yasmin, BAY86-5131) | Total |
|---|---|---|---|
| 0 | 216 | 206 | 422 |
| 1 | 39 | 49 | 88 |
| 2 | 19 | 24 | 43 |
| 3 | 4 | 2 | 6 |
| 4 | 1 | 0 | 1 |
Ran from Jan 2011 to primary completion in Jan 2013, 24 months.
Results were first posted in Apr 2014, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.